iBio Q1 Revenue Surges to $100,000, Promising Therapy IBIO-610 Showcases Long-Acting Potential, But Faces Financial Challenges

iBio Inc. reported Q1 revenue of $100,000, exceeding the consensus estimate of $25,000. The company is advancing its novel therapy, IBIO-610, which shows potential for infrequent dosing, enhancing patient adherence. However, iBio faces financial challenges with significant negative margins and a distressed Altman Z-Score. The company must address these challenges to ensure long-term viability and investor confidence.